Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gamma-aminobutyric acid + gabapentin
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
gamma-aminobutyric acid + gabapentin is a nonproprietary combination of gamma-aminobutyric acid and gabapentin. Gabapentin is a small-molecule gabapentinoid used clinically as an anticonvulsant and analgesic; its accepted primary mechanism is binding to the alpha-2-delta auxiliary subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release in the central nervous system. Gamma-aminobutyric acid is the principal inhibitory neurotransmitter in the brain, but as an exogenous oral ingredient it has limited blood-brain barrier penetration and is more commonly encountered in supplement-type products than in standard prescription pharmaceutical development. The exact fixed-dose product, developer, manufacturer, dosage form, and approved indication for the specific combination name provided are not clearly established from the name alone, so this entry should be interpreted as a combination concept rather than a well-defined marketed branded drug.
- Other names
- gamma-aminobutyric acid + gabapentinGABA + gabapentin
02
Targets
CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA2D2 (α2δ-2)
Beyond the preview
Go deeper on gamma-aminobutyric acid + gabapentin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gamma-aminobutyric acid + gabapentin.